NTRR NEUTRA CORP.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1512886 · Fiscal year ends 01/31
Financial factors as of 2023-10-31 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.7%
TTM net income YoY-2.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-1,457.1%
Net margin-2,723.6%
FCF margin—
EBITDA margin-1,103.4%
Returns
ROE—
ROA-758.7%
ROIC (approx.)—
Asset turnover0.28x
Leverage & solvency
Liabilities / assets3,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage-14.07x
Cash quality & payout
Operating cash flow / net income0.02x
Accruals ratio-743.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-01-31 | FY20222022-01-31 | FY20212021-01-31 | FY20202020-01-31 | FY20192019-01-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $67,996 | $92,014 | $9,687 | $6,395 | — |
| Cost of revenue | $32,690 | $60,853 | $42,944 | — | — |
| Gross profit | $35,306 | $31,161 | -$33,257 | $6,395 | — |
| SG&A expense | $227,974 | $508,482 | $414,742 | $400,640 | $1.71M |
| Operating income | -$297,675 | -$583,582 | -$478,665 | -$394,245 | -$1.71M |
| Interest expense | $62,063 | $60,606 | $121,648 | $340,701 | $720,750 |
| Pretax income | -$557,894 | -$632,926 | — | — | — |
| Income tax | $3,523 | — | $3,523 | $0 | — |
| Net income | -$561,417 | -$632,926 | -$538,892 | -$695,621 | -$2.43M |
| EBITDA | -$218,769 | -$505,797 | -$447,999 | — | — |
| EPS (basic) | — | — | 0.00 | 0.00 | -0.16 |
| EPS (diluted) | — | — | 0.00 | 0.00 | -0.16 |
| Weighted avg. shares (diluted) | — | — | 1.19B | 241.54M | 14.91M |
| Balance sheet | |||||
| Cash & equivalents | $1,969 | $1,056 | $23,308 | $177,176 | $0 |
| Receivables | — | — | $25 | — | — |
| Inventory | $23,846 | — | — | $3,500 | — |
| Current assets | $25,815 | $2,666 | $24,943 | $182,334 | $163,596 |
| PP&E, net | $49,360 | $128,266 | $165,824 | — | — |
| Total assets | $75,175 | $130,932 | $190,767 | $182,334 | $163,596 |
| Current liabilities | $759,639 | $1.15M | $1.00M | $1.03M | $1.27M |
| Total liabilities | $813,795 | $1.15M | $1.00M | $1.03M | $1.27M |
| Shareholders' equity | -$773,820 | -$1.27M | -$967,476 | -$849,490 | -$1.11M |
| Shares outstanding | 2.74B | 1.78B | 1.49B | 616.20M | 34.13M |
| Cash flow statement | |||||
| Operating cash flow | -$153,243 | -$405,615 | -$412,378 | -$181,607 | -$417,000 |
| Capital expenditure | — | $40,227 | $196,490 | — | — |
| Free cash flow | — | -$445,842 | -$608,868 | — | — |
| Investing cash flow | — | -$40,227 | -$196,490 | — | — |
| Financing cash flow | $154,156 | $423,590 | $455,000 | $358,783 | $417,000 |
| Depreciation & amortization | $78,906 | $77,785 | $30,666 | — | — |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.